Press Releases

 
Fatcamera_469174596.jpg

Cullgen Announces Expanded Scientific Advisory Board

July 18, 2018 - DELAWARE - Cullgen Inc, (“Cullgen” or the “Company), a drug discovery company focused on development of drug candidates using uSMITE™ (ubiquitin mediated small molecule induced target elimination), announced that Dr. Timothy Heffernan and Dr. Michele Pagano have joined the Company’s Scientific Advisory Board (SAB).


Fatcamera_672136720.jpg

Executives of Cullgen to Present at International Conferences

July 11, 2018 - DELAWARE - Executives of Cullgen Inc. ("Cullgen") have been invited to present research findings at three international drug discovery conferences in US and China.


Fatcamera_488615286.jpg

Cullgen Announces Publication by Co-Founders in European Journal of Medicinal Chemistry

April 3, 2018 - DELAWARE - Cullgen Inc., a biopharmaceutical company focusing on developing new drugs using protein degradation technology today announced that the laboratories of its co-founders, Dr. Jian Jin and Dr. Yue Xiong, have published an article in European Journal of Medicinal Chemistry featuring first-in-class small-molecule degraders of Anaplastic Lymphoma Kinase.


Fatcamera_939775980.jpg

Cullgen Announces Seed Financing

March 1, 2018 - TOKYO, JAPAN – Cullgen Inc. ("Cullgen") today announced a Seed Financing of up to $15M by GNI Group Ltd. (GNIG) (TOKYO: 2160) to build a new drug discovery platform based on advanced ubiquitin-mediated protein degradation technology.